

Single-Patient Nurse Mixing Instruction Sheet

Non-24/7 Pharmacies and Free-Standing Emergency Department

labetalol 500 mg/100 mL IV Infusion

SUPPLIES include quantity and medication name, strength/concentration, volume, diluent, diluent volume, and quantity and name of each supply needed

NS flush syringes are never to be used for reconstitution/diluent for medication.

- Labetalol 5 mg/mL injection vial (20 mL or 40 mL vial depending on availability):
 - o 20 mL: use five (5) vials

or

- o 40 mL: use three (3) vials
- Alcohol swabs
- One (1) #18 gauge needle preferred (20-23 gauge needles acceptable)
- One (1) 50 mL sterile IV syringe
- One (1) empty, sterile bag (100 mL)
- Nursing IV admixture label(s) Lawson # 626

STEPS explicitly state each step in chronological order, including hand washing, gown/garb, alcohol swab, etc.)

- 1. Wash hands. Prepare/clean the designated mixing area.
- 2. Flip the cap off of the labetalol 5 mg/mL injection vial, wipe the rubber stoppers with alcohol swab, and wipe the injection port of the empty bag.
- 3. Attach #18 gauge needle to syringe. Withdraw a total of 100 mL from labetalol 5 mg/mL injection vials.
- 4. Transfer 100 mL of labetalol 5 mg/mL injection into the empty, sterile bag. Discard syringe with needle into a sharp container.
- 5. Do not shake. Visually inspect solution (e.g. free of inappropriate visible particulates or other foreign matter, discoloration, and defect), and the container integrity is intact. Discard if any defects.
- 6. Label the labetalol 500 mg/100 mL infusion bag with:
 - a. Drug name, strength, and dose (if not apparent by the container)
 - b. Diluent and volume (if not apparent by the container)
 - c. Hang-by date and time (administration must begin within 1 hour from the time of compounding)
 - d. Initials of person compounding

NOTES explicitly state (if applicable) any pertinent information

Protect final product from light. Cover with light protected plastic bag (e.g. brown plastic bag).

References

- Labetalol injection [prescribing information]. Lehi, Utah: Civica Inc. Revised 10/2019. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d7c53b1c-b6a5-482a-a7c8-7425d9cd9ef8&type=display.
- United States Pharmacopeia (USP). General Chapter, <797> Pharmaceutical Compounding—Sterile Preparations. (2023) USP-NF.
 Rockville, MD: United States Pharmacopeia.

https://ochsnerhealth.sharepoint.com/sites/ClinicalResources/SiteAssets/Forms/AllItems.aspx?id=%2Fsites%2FClinicalResources%2FSiteAssets%2FSitePages%2FRegulatory%2DReadiness%2FUSP%2D797%2DOfficial%2D11%2E1%2E23%2Epdf&parent=%2Fsites%2FClinicalResources%2FSiteAssets%2FSiteAssets%2FSitePages%2FRegulatory%2DReadiness.